Physician profile
Mamta Varshney
NPI 1205869443
$1,191.93
in general payments reported to CMS, 2019-2025
19 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.43 · 2020: $52.27 · 2021: $156 · 2022: $225 · 2023: $314 · 2024: $207 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $306.57 | 2021-2025 | |
| Lilly USA, LLC | $205.90 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $89.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $86.53 | 2020-2022 | |
| Amgen INC. | $80.94 | 2023-2025 | Otezla, Repatha, Repatha |
| Gilead Sciences, INC. | $66.83 | 2019-2023 | |
| Dexcom, INC. | $66.54 | 2023-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $42.12 | 2019 | |
| Esperion Therapeutics, INC. | $39.10 | 2021-2023 | Nexletol |
| Hologic Sales and Service, LLC | $34.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $32.05 | 2023 | Breztri |
| Merck Sharp & Dohme LLC | $26.87 | 2019 | |
| Allergan, INC. | $19.10 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2021 | |
| Abbott Laboratories | $17.31 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $16.89 | 2021 | |
| Glaxosmithkline, LLC. | $16.80 | 2024 | Shingrix, Arexvy |
| Inogen, INC. | $13.42 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.36 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Varshney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.